Iron, an essential mineral taken orally or by infusion, is used to correct iron deficiency. In true deficiency, it restores blood levels, eases fatigue in women with low stores, relieves restless legs and, by infusion, reduces hospital stays in heart failure. Oral iron commonly causes digestive side effects. People with full stores gain nothing measurable, and build-up concerns lack trial confirmation. The evidence favors testing-guided correction over general longevity use. (Full Review)
| Marker | Target | Why |
|---|---|---|
| Serum ferritin | 50–200 μg/L | Iron stores; safety check for excess |
| Transferrin saturation | 20–50% | Safety check for overload |
| Hemoglobin (complete blood count) | 12.0–15.5 g/dL women, 13.5–17.5 g/dL men | Response in anemia |
| C-reactive protein (CRP) | Not specified in the ER | Interpret ferritin |
| Serum phosphate (intravenous ferric carboxymaltose only) | 2.5–4.5 mg/dL | Safety check before repeat courses |
| HFE genotype (C282Y, H63D) | No established target; record genotype once | Safety check for overload risk |
Cadence: Baseline before starting, fasting in the morning; hemoglobin at 2–4 weeks; ferritin and transferrin saturation at 8–12 weeks, then every 6–12 months while risk factors persist; phosphate before each repeat ferric carboxymaltose course; HFE genotyping once when transferrin saturation is high or a relative has hemochromatosis